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Human 60-kDa Heat Shock Protein Is a Target Autoantigen of
T Cells Derived from Atherosclerotic Plaques1
Marisa Benagiano,2* Mario M. D’Elios,2*† Amedeo Amedei,*† Annalisa Azzurri,*
Ruurd van der Zee,‡ Alessandra Ciervo,§ Gianni Rombola`,† Sergio Romagnani,*†
Antonio Cassone,§ and Gianfranco Del Prete3*†
Epidemiological studies suggest the potential importance of an inflammatory component in atherosclerosis and support the
hypothesis that immune responses to Ags of pathogens cross-react with homologous host proteins due to molecular mimicry.
Protein candidates involved may be the stress-induced proteins known as heat shock proteins (HSP). In this study, we report that
atherosclerotic plaques harbor in vivo-activated CD4 T cells that recognize the human 60-kDa HSP. Such in vivo-activated
60-kDa HSP-specific T cells are not detectable in the peripheral blood. In patients with positive serology and PCR for Chlamydia
pneumoniae DNA, but not in patients negative for both, most of plaque-derived T cells specific for human 60-kDa HSP also
recognized the C. pneumoniae 60-kDa HSP. We characterized the submolecular specificity of such 60-kDa HSP-specific plaque-
derived T cells and identified both the self- and cross-reactive epitopes of that autoantigen. On challenge with human 60-kDa HSP,
most of the plaque-derived T cells expressed Th type 1 functions, including cytotoxicity and help for monocyte tissue factor
production. We suggest that arterial endothelial cells, undergoing classical atherosclerosis risk factors and conditioned by Th type
1 cytokines, express self 60-kDa HSP, which becomes target for both autoreactive T cells and cross-reactive T cells to microbial
60-kDa HSP via a mechanism of molecular mimicry. This hypothesis is in agreement with the notion that immunization with HSP
exacerbates atherosclerosis, whereas immunosuppression and T cell depletion prevent the formation of arteriosclerotic lesions in
experimental animals. The Journal of Immunology, 2005, 174: 6509–6517.
A therosclerosis is a multifactorial disease for which anumber of different pathogenic mechanisms have beenproposed. In the last two decades, attention has been
given to the inflammatory processes associated with atherogenesis.
In addition to classical risk factors for atherosclerosis, such as high
levels of low-density lipoprotein (LDL)4 cholesterol or oxidized
LDL, free radicals, hyperglycemia, and genetic susceptibility to
endothelial damage (1, 2), a pathogenic role for infections in ath-
erosclerosis is suggested by the detection of pathogens (e.g., Chla-
mydia pneumoniae, CMV, or herpes viruses) in the arterial vessels
and the association between atherosclerosis and increased Ab lev-
els to these pathogens (3). Observations in humans and animals
suggest that atherosclerotic plaques derive from specific cellular
and molecular mechanisms that can be ascribed to an inflammatory
disease of the arterial wall, the lesions of which consist of mac-
rophages and T lymphocytes (4–6). Activated macrophages and T
cells would be responsible for in situ production of enzymes, cy-
tokines, and chemokines that further expand the process. If inflam-
mation continues unabated, it results in increased numbers of
plaque-infiltrating macrophages and T cells, which contribute to
remodeling of the arterial wall (7). Within the T cell population of
the plaque, most of the cells are activated CD4 cells expressing
HLA-DR and CD25 of the IL-2R (8). C. pneumoniae DNA and C.
pneumoniae-specific T cell clones were found in the plaques of
anti-C. pneumoniae seropositive patients. The specificity reper-
toire of such CD4 T cells included the C. pneumoniae 60-kDa
heat shock protein (CpHSP60), the 10-kDa HSP, the outer mem-
brane protein 2, or undefined Ags of the C. pneumoniae elemen-
tary bodies. T cell clones recovered from C. pneumoniae DNA-
negative plaques of anti-C. pneumoniae seronegative patients did
not react to C. pneumoniae Ags (9).
In this study, we focused on the analysis of the T cell infiltrates
of atherosclerotic plaques of anti-C. pneumoniae seronegative pa-
tients, making the hypothesis that human proteins expressed under
stress conditions, such as the human 70-kDa HSP (hHSP70) or
human 60-kDa HSP (hHSP60), might be autoantigens recognized
by plaque-infiltrating T cells.
Materials and Methods
Patients
Carotid plaques were obtained by endoarterectomy from eight patients
(five males and three females; mean age, 67 years; range, 62–73 years)
with atherosclerotic arteriopathy. Four patients were seronegative for anti-
C. pneumoniae Abs (Cp-neg), whereas the other four patients were sero-
positive for anti-C. pneumoniae Abs (Cp-pos), as shown by both commer-
cial ELISA tests (Eurospital) and standard microimmunofluorescence
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assay (cutoff value, 32). Samples of PBMC were obtained from each pa-
tient. Their MHC haplotypes were as follows: HLA-A2, B7, B51,
DRB1*14, and DRB1*16 in patient 1; HLA-A1, A2, B13, B18, DRB1*03,
and DRB1*07 in patient 2; HLA-A24, B15, B40, DRB1*01, and DRB1*16
in patient 3; HLA-A1, A2, B18, DRB1*04, and DRB1*11 in patient 4;
HLA-A24, B44.03, B58.01, DRB1*0701, and DRB1*16 in patient 5;
HLA-A2, B15, B44, and DRB1*13 in patient 6; HLA-A1, B8, B27,
DRB1*03, and DRB1*07 in patient 7; and HLA-A2, A24, B7, B51,
DRB1*0701, and DRB1*11 in patient 8.
Detection of C. pneumoniae in atherosclerotic plaques
The presence of C. pneumoniae was investigated by nested PCR, as reported
elsewhere (9, 10). Briefly, DNA was extracted from fragments of all the en-
doarterectomy specimens by QIAamp DNA kit (Qiagen). Nested PCR con-
sisted of two rounds of amplification using two sets of primers, each in a 50-l
volume. On completion of primary PCR (37 cycles), 2 l of the PCR product
were added into fresh reaction mix containing the second set of primers and
amplified for 25 cycles. The amplified DNA products were analyzed by elec-
trophoresis in 1.5% agarose gel, stained with ethidium bromide, and hybrid-
ized as reported previously (10). The nested PCR for C. pneumoniae included
an outer primer pair (HL-1, HR-1) and an inner pair (HM-1, HR-2) that gen-
erated a product of 204 bp. The details of primers and probe are as follows:
HL-1, -5-GTTGTTCATGAAGGCCTACT-3 end; HR-1, -5-TGCATAAC
CTACGGTGTGTT-3 end; HM-1, -5-GTGTCATTCGCCAAGGTTAA-3
end; HR-2, -5-ACCTGTCCAAGGTTCATCCT-3 end; and DNA probe,
-5-GTGTCATTCGCCAAGGTTAAAGTCTACGTT-3 end.
Generation of T cell clones from atherosclerotic plaques and
peripheral blood
Fragments of atherosclerotic plaques and samples of PBMC were cultured
for 7 days in RPMI 1640 medium supplemented with IL-2 to expand in
vivo-activated T cells. Single T cell blasts were then cloned under limiting
dilution (9, 11–13). Briefly, single T cell blasts were seeded in microwells
(0.3 cells/well) in the presence of 2  105 irradiated (5000 rad) allogeneic
PBMC, PHA (0.5% vol/vol), and IL-2 (50 U/ml). At weekly intervals,
irradiated allogeneic PBMC and IL-2 were added to each microculture to
maintain the expansion of growing clones. Ag specificity of T cell clones
was assessed by measuring [3H]thymidine uptake after 60 h of coculture
with irradiated autologous PBMC in the presence of medium, recombinant
hHSP70 (Sigma-Aldrich) (10 g/ml), recombinant hHSP60 (Sigma-Al-
drich) (10 g/ml), or recombinant CpHSP60 (10 g/ml), prepared as en-
dotoxin-free material (14). No significant proliferation of T cell clones was
found in response to irradiated autologous PBMC alone. The mitogenic
index (MI) was calculated as the ratio between mean values of cpm ob-
tained in stimulated cultures and those obtained in the presence of medium
alone. MI 5 was considered positive.
T cell clones reactive to hHSP60 were also tested for proliferation in
response to the recombinant HSP65 protein of Mycobacterium bovis ba-
cillus Calmette-Gue´rin (BCG) (MbHSP65) (Aalto Bio Reagents) and to the
recombinant 60-kDa chaperonin GroEL of Escherichia coli (Sigma-Al-
drich) (10 g/ml).
All of the 26 plaque-derived T cell clones reactive to hHSP60 and the 18
clones reactive to both hHSP60 and CpHSP60 expressed a
CD3CD4CD8 phenotype and showed a single peak of fluorescence
intensity. The repertoire of the TCR V chain of HSP60-specific T cell
clones was analyzed with a panel of 22 mAbs specific to the following:
V1, V2, V4, V7, V9, V11, V14, V16, V18, V20, V21.3,
V22, and V23 (Beckman Coulter Immunotech); and V3.1, V5.1,
V5.2, V5.3, V6.7, V8, V12, V13, and V17 (AMS Biotechnol-
ogy); and isotype-matched nonspecific Ig were used as negative control.
Data acquisition was performed in a FACSCalibur flow cytometer using
the CellQuest software program (BD Biosciences). From each T cell clone,
mRNA was extracted by mRNA direct isolation kit (Qiagen). For cDNA
synthesis, the same amount of mRNA (50 ng) was used, and cDNA was
synthesized by Moloney murine leukemia virus-reverse transcriptase (New
England Biolabs) and oligo(dT) primers according to enzyme supplier’s
protocol. cDNA mix of all samples was amplified under equal conditions
by a 30-cycle PCR using a V TCR typing amplimer kit for V10, V15,
and V19 (BD Clontech) according to the manufacturer’s instructions.
Submolecular specificity of plaque-derived T cell clones reactive
to hHSP60 or to both hHSP60 and CpHSP60
To span the 573 aa sequence of hHSP60 and the 544 aa sequence of
CpHSP60, 113 and 107 overlapping 15-mer peptides with a 10 (5 on each
side) aa overlap, respectively, were prepared by automated, simultaneous
multiple peptide synthesis, as described previously (15) Homologies be-
tween the two series of peptides were screened by using the basic local
alignment search tool server of the National Center for Biotechnology
Information.
Two series of 15-mer peptides corresponding to a number of sequences
of the HSP65 protein of M. bovis BCG (MbHSP65) and of the 60-kDa
chaperonin GroEL of E. coli (aa 21–35, 26–40, 31–45, 46–60, 51–65,
56–70, 121–136, 126–140, 131–145, 141–155, 146–160, 151–165, 161–
175, 166–180, 171–185, 181–195, 186–200, 191–205, 211–225, 216–230,
221–235, 406–420, 411–425, 416–430, 421–435, and 426–440) were
also prepared. Equal amounts of each component of the two series of over-
lapping peptides of hHSP60 and of CpHSP60 were pooled to have two
series of 11 peptide pools. T cell blasts (4  104) from each clone were
cultured in triplicate for 3 days together with irradiated autologous mono-
nuclear cells (1.5  105) in the presence of medium, hHSP60 (10 g/ml),
CpHSP60 (10 g/ml), or equal aliquots from each of the 22 pools in which
each peptide component was present at a 10 g/ml final concentration.
After 60 h, [3H]TdR uptake was measured. T cell blasts of each clone were
then retested for proliferation to the individual peptide components of the
pool that had induced a MI 5.
MHC class II restriction of hHSP60 epitope recognition by
plaque-derived T cell clones
The effect of anti-HLA-DR (clone G46–6) or anti-HLA-DQ (clone
TU169; BD Biosciences Pharmingen) (5 g/ml final concentration) mAbs
or their isotype control (mouse IgG2a) on T cell clone proliferation induced
by hHSP60 or CpHSP60 was assessed. The MHC class II restriction of the
proliferative response of T cell clones to hHSP60 or CpHSP60 peptides
was assessed by using irradiated allogeneic APC. To this end, PBMC from
both patients and healthy donors sharing with patients one of the DRB1*
alleles were stimulated with PHA followed by IL-2 to obtain polyclonal
lines of activated T cells to be used as irradiated (3000 rad) allogeneic APC
in coculture experiments with T cell clones in the presence of the HSP60
peptide to which they reacted.
Assessment of the cytokine profile of T cell clones
To assess the cytokine production of hHSP60-specific clones on Ag stim-
ulation, 5  105 T cell blasts of each clone were cocultured for 48 h in 0.5
ml of medium with 5  105 irradiated autologous PBMC in the absence or
presence of hHSP60 or CpHSP60 (10 g/ml). At the end of culture period,
duplicate samples of each supernatant were assayed for IFN-, TNF-, and
IL-4 (BioSource International) (9, 13). T cell clones able to produce IFN-,
but not IL-4, were categorized as Th1; clones able to produce IL-4, but not
IFN-, were categorized as Th2; and clones producing both IFN- and IL-4
were categorized as Th0.
Perforin-mediated cytotoxicity and Fas-Fas ligand-mediated
proapoptotic activity
Perforin-mediated cytolytic activity of T cell clones was assessed as re-
ported previously (16). T cell blasts of hHSP60-specific clones were in-
cubated at ratios of 10:1, 5:1, and 2.5:1 with 51Cr-labeled autologous EBV
transformed B (EBV-B) cells preincubated with hHSP60 (10 g/ml). After
centrifugation, microplates were incubated for 8 h at 37°C, and 0.1 ml of
supernatant was removed for measurement of 51Cr release, as reported
previously (17). The ability of hHSP60-specific T cell clones to induce Fas-Fas
ligand-mediated apoptosis was assessed using Fas Jurkat cells as target. T
cell blasts from each clone were cocultured with 51Cr-labeled Jurkat cells at
E:T ratios of 10:1, 5:1, and 2.5:1 for 18 h in the presence of PMA (10 ng/ml)
and ionomycin (1 mmol/l), as reported previously (17, 18).
Assay for T cell clone helper function for monocyte tissue factor
(TF) production
T cell blasts of hHSP60-specific clones (8  105/ml) were cocultured for
16 h with autologous monocytes (4  105/ml) in the presence of medium,
hHSP70 (10 g/ml), hHSP60 (10 g/ml), or CpHSP60 (10 g/ml). At the
end of culture period, TF protein was measured by a specific ELISA
(American Diagnostica) in duplicate samples of the supernatants obtained
from cell suspensions after solubilization of membrane proteins with Triton
X-100 and ultracentrifugation, as reported previously (19).
Results
Autoreactive CD4 T cell clones specific for hHSP60 are
present in atherosclerotic lesions
In vivo-activated T cells resident in the plaques or in the peripheral
blood were expanded in vitro in IL-2-conditioned medium and
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then cloned by a procedure that has proved useful and accurate for
studies of tissue-infiltrating T cells in various diseases (9, 11–13).
A total number of 151 CD4 and 23 CD8 T cell clones were
obtained from the plaques of the four Cp-neg patients, whereas 115
CD4 and 21 CD8 were the T cell clones derived from the
plaques of the four Cp-pos patients. Nested PCR on endarterec-
tomy specimens showed C. pneumoniae genomic material in each
of the plaques obtained from the four Cp-pos patients but not in the
plaques from the Cp-neg patients (data not shown).
For each patient, randomly selected CD4 and CD8 T cell clones
derived from PBMC were matched to the corresponding plaque-de-
rived T cell clones and assayed for proliferation in response to
Table 1. Atherosclerotic plaques, but not peripheral blood, harbor CD4 T cells specific for hHSP60a
Patients and Source of T Cells
Total Number of CD4 T cell
Clones Tested
Number (%) of Clones Reactive to
hHSP60 Both hHSP60 and CpHSP60
C. pneumoniae-negative patients
1. Plaque 40 6 (15) 0
PBMC 40 0 0
2. Plaque 38 6 (16) 0
PBMC 38 0 0
3. Plaque 36 5 (14) 0
PBMC 36 0 0
4. Plaque 37 4 (11) 0
PBMC 37 0 0
C. pneumoniae-positive patients
5. Plaque 20 7 (35) 5/7 (71)
PBMC 20 0 0
6. Plaque 25 3 (12) 3/3 (100)
PBMC 25 0 0
7. Plaque 33 6 (18) 4/6 (67)
PBMC 33 0 0
8. Plaque 37 7 (19) 6/7 (86)
PBMC 37 0 0
a Equal numbers of clones derived from plaques or PBMC were screened for responsiveness to hHSP60 and CpHSP60 in
the presence of irradiated autologous mononuclear cells by measuring 3[H]-thymidine uptake after 60 h.
Table II. Epitope specificity of plaque-derived CD4 T cell clones reactive to hHSP60 but not to CpHSP60a
T Cell Clone (TCR V)
Proliferative Response (MI) to
Peptide Amino Acid Sequence (position)hHSP70 hHSP60 hHSP60 Peptide
1.10 (V11) 2 36 49 MLRLPTVFRQMRPVS (1–15)
1.30 (V1) 2 27 53 MRPVSRVLAPHLTRA (11–25)
1.54 (V17) 2 21 23 VKDGKTLNDELEIIE (201–215)
1.26 (V5.1) 2 92 118 LEIANAHRKPLVIIA (261–275)
1.43 (V18) 2 102 97 TLNLEDVQPHDLGKV (331–345)
1.08 (V7) 2 111 78 MAGDFVNMVEKGIID (506–520)
2.14 (V14) 2 168 139 TVFRQMRPVSRVLAP (6–20)
2.08 (V20) 2 69 84 KFGADARALMLQGVD (31–45)
2.58 (V21.3) 2 46 52 KLVQDVANNTNEEAG (96–110)
2.40 (V5.2) 2 91 68 NPVEIRRGVMLAVDA (136–150)
2.53 (V2) 2 47 71 GGAVFGEEGLTLNLE (321–335)
2.11 (V6.7) 2 63 88 MAGDFVNMVEKGIID (506–520)
3.18 (V8) 2 473 439 TVFRQMRPVSRVLAP (6–20)
3.40 (V4) 2 28 42 KNIGAKLVQDVANNT (91–105)
3.53 (V12) 2 144 198 RRGVMLAVDAVIAEL (141–155)
3.43 (V3.1) 2 19 28 TLNDELEIIEGMKFD (206–220)
3.24 (V16) 2 467 488 MAGDFVNMVEKGIID (506–520)
4.13 (V9) 2 126 184 MLRLPTVFRQMRPVS (1–15)
4.07 (V4) 2 52 41 PYFINTSKGQKCEFQ (226–240)
4.31 (V22) 2 29 33 EIIKRTLKIPAMTIA (466–480)
4.25 (V11) 2 68 91 VEKIMQSSSEVGYDA (491–505)
5.02 (V8) 2 55 63 MRPVSRVLAPHLTRA (11–25)
5.14 (V12) 2 71 113 GGAVFGEEGLTLNLE (321–335)
7.31 (V14) 2 80 98 TVFRQMRPVSRVLAP (6–20)
7.12 (V11) 2 32 47 MAGDFVNMVEKGIID (506–520)
8.30 (V5.2) 2 102 178 MLRLPTVFRQMRPVS (1–15)
a T cell blasts from each clone were cocultured with irradiated autologous APC in the presence of medium alone, hHSP70, hHSP60, or hHSP60
peptides (10 g/ml), and proliferative responses (MI) were measured after 3 days. Results are reported as mean values obtained in quadruplicate cultures,
SD values being 14% of means. Letters underlined in the recognized hHSP60 peptides indicate the amino acids shared with CpHSP60 along the
sequence. Patients 1–4 were anti-C. pneumoniae seronegative, whereas patients 5–8 were seropositive.
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hHSP70, hHSP60, and CpHSP60. None of the CD8 clones derived
from either plaques or PBMC showed proliferation to those Ags.
Likewise, none of the 266 CD4 clones generated from the PBMC of
either Cp-neg or Cp-pos patients showed significant proliferation to
the Ags tested (Table I), although they proliferated in response to
mitogen stimulation (data not shown). In contrast, a variable propor-
tion between 11 and 35% of the CD4 T cell clones generated from
plaque-infiltrating T cells of either Cp-neg or Cp-pos patients prolif-
erated significantly to hHSP60 (Table I) but not to hHSP70 Ag (MI
2). Under the same conditions, none of the 21 hHSP60-specific
CD4 clones from the plaques of the four Cp-neg patients prolifer-
ated significantly to CpHSP60. In contrast, in the series of the 23
hHSP60-specific CD4 clones from the plaques of the four Cp-pos
patients, 18 (78%) proliferated equally well to both hHSP60 and
CpHSP60 (Table I). Evidence for clonality of the CD3CD4CD8
T cell clones, which is critical for interpretation of data, was provided
by the cytofluorimetric patterns of single TCR-V expression and the
staining by only one of the TCR-V-chain-specific mAbs, with a
single peak of fluorescence intensity (data not shown).
Submolecular specificity of autoreactive hHSP60-specific T cell
clones
T cell blasts from each of the T cell clones reactive to hHSP60, but
not to CpHSP60, were screened for proliferation in response to the
113 overlapping peptides for the hHSP60 (Table II). Each of these
autoreactive T cell clones proliferated almost equally well to both
the entire hHSP60 protein and to an epitope of such autoantigen.
Interestingly, some hHSP60 epitopes, such as the 1–15, 6–20, and
506–520, were recognized by clones from different donors, despite
their different MHC class II haplotypes or different TCR-V ex-
pression by T cell clones (Table II). Also, the five T cell clones
recovered from atherosclerotic plaques of Cp-pos patients that pro-
liferated to hHSP60, but not to CpHSP60, recognized the 1–15,
6–20, 11–25, 321–335, and 506–520 epitopes of hHSP60 (Table
II). The lack of responsiveness to CpHSP60 of the 26 hHSP60-
specific clones was confirmed by their inability to proliferate in
response to the CpHSP60 peptide corresponding to the hHSP60
epitope to which they were reactive (data not shown), although a
number of the hHSP60 epitopes recognized by this series of clones
shared a few (up to 7) amino acids with the corresponding
CpHSP60 peptides (Table II).
Each of the 18 T cell clones that proliferated to both hHSP60
and CpHSP60 was screened for proliferation in response to the 113
overlapping peptides for the hHSP60 and the 107 peptides for the
CpHSP60 (Table III). As expected, each of these cross-reactive T
cell clones proliferated not only to both the entire hHSP60 protein
and to an epitope of such autoantigen but also to the entire
CpHSP60 and to a CpHSP60 peptide. However, the relevant cross-
reactive CpHSP60 peptides showed high-sequence homology
(from 7 to 12 of 15 aa) to the corresponding stimulatory hHSP60
epitopes. Interestingly, the panel of hHSP60 epitopes recognized
by cross-reactive clones included 18 different peptides, with only
some overlap, mainly in the 436–460 aa sequence for clones 7.03
and 7.22 of patient 7 and clone 8.14 of patient 8 (Table III).
Due to the high homology between the human and the bacterial
60-kDa HSPs, all of the hHSP60-specific clones were tested for
their ability to proliferate in response to graded concentrations of
the MbHSP65 of BCG or to the 60-kDa chaperonin GroEL of E.
coli. None of the 26 T cell clones reactive to hHSP60, but not to
CpHSP60, showed detectable proliferation to MbHSP65 or to
GroEL, even at a dose as high as 50 g/ml (data not shown). In
contrast, 11 of the 18 T cell clones reactive to both hHSP60 and
CpHSP60 also showed poor, but detectable, reactivity (range of
MI, 2.8–16.1) to comparable concentrations of MbHSP65. How-
ever, at MbHSP65 concentrations2 g/ml, none of the 11 clones
showed MI 2. Likewise, 9 of the same 18 clones showed poor
reactivity to GroEL (range of MI, 2.4–17.2), but at lower Ag doses
(2 g/ml) no proliferation was detectable. Each of the 11 clones
potentially cross-reactive to MbHSP65 and each of the 9 clones
potentially cross-reactive to GroEL were also tested for prolifera-
tion in response to the MbHSP65 and GroEL peptides that partially
overlapped their specific hHSP60/CpHSP60 epitopes. As shown in
Table IV, at a concentration of 1 g/ml, neither MbHSP65 nor
GroEL proteins or their potentially relevant peptides were able to
induce T cell clone proliferation, whereas both hHSP60 and
CpHSP60 and their relevant peptides were still stimulatory. It is
interesting to note that a single amino acid difference (S instead of T
at position 79 of hHSP60 or at position 55 of CpHSP60) accounted
Table III. Epitope specificity of CD4 T cell clones reactive to both hHSP60 and CpHSP60 obtained from the atherosclerotic plaques of anti-C.
pneumoniae seropositive patientsa
T Cell Clone (TCR V)
Proliferative Response (MI) to
hHSP60 hHSP60 Peptide (sequence) CpHSP60 CpHSP60 Peptide (sequence)
5.05 (V17) 38 81 (DGVTVAKSIDLKDKY 76–90) 73 89 (KDGVTVAKEIELEDK 51–65)
5.16 (V11) 75 113 (EEIAQVATISANGDK 166–180) 43 107 (HKEIAQVATISANND 141–155)
5.19 (V13.1) 49 37 (DAYVLLSEKKISSIQ 241–255) 67 44 (EDAL I LIYDKKISGI 216–230)
5.18 (V14) 20 33 (VGGTSDVEVNEKKDR 406–420) 31 39 (VGAATEIEMKEKKDR 381–395)
5.12 (V9) 34 61 (PTKVVRTALLDAAGV 521–535) 22 58 (LDPTKVTRSALESAA 496–510)
6.37 (V5.1) 107 76 (TVIIEQSWGSPKVTK 61–75) 88 51 (RHVVIDKSFGSPQVT 36–50)
6.08 (V14) 23 57 (VIAELKKQSKPVTTP 151–165) 21 48 (VVVDELKKISKPVQH 126–140)
6.41 (V8) 33 27 (LKVGLQVVAVKAPGF 291–305) 29 41 (RLRAGFRVCAVKAPG 266–280)
7.18 (V9) 44 61 (LLADAVAVTMGPKGR 46–60) 21 67 (KTLAEAVKVTLGPKG 21–35)
7.16 (V4) 89 113 (LEIIEGMKFDRGYIS 211–225) 147 131 (VLDVVEGMNFNRGYL 186–200)
7.03 (V1) 45 37 (GCALLRCIPALDSLT 441–455) 28 42 (GTALVRCIPTLEAFL 416–430)
7.22 (V13.2) 121 215 (RCIPALDSLTPANED 446–460) 120 91 (RCIPTLEAFLPMLAN 421–435)
8.22 (V18) 51 78 (VAVTMGPKGRTVIIE 51–65) 39 71 (AVKVTLGPKGRHVVI 26–40)
8.26 (V12) 136 104 (VATISANGDKEIGNI 171–185) 96 122 (QVATISANNDSEIGN 146–160)
8.01 (V5.2) 27 40 (KKVGRKGVITVKDGK 191–205) 23 31 (MEKVGKNGSITVEEA 166–180)
8.14 (V9) 76 68 (IVLGGGCALLRCIPA 436–450) 71 89 (ILPGGGTALVRCIPT 411–425)
8.07 (V22) 417 398 (VNMVEKGIIDPTKVV 511–525) 548 377 (AYTDMIDAGILDPTK 486–500)
8.18 0(V11) 142 201 (ASLLTTAEVVVTEIP 536–550) 170 226 (LLTTEALIADIPEEK 516–530)
a Culture conditions are reported in the legend to Table II. Underlined letters indicate the amino acids shared between hHSP60 and CpHSP60.
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for a strong reduction of stimulation of clone 5.05. Likewise, a single
amino acid change (N instead of T at position 61 of hHSP60)
hampered the recognition by clone 8.22 of the 26–40 epitope of either
MbHSP65 or GroEL, whereas the substitution of T with H at position
37 of CpHSP60 did not affect cross-recognition.
The relative potency in inducing T cell clone proliferation of the
self (hHSP60) and/or the corresponding cross-reactive CpHSP60
protein and peptides was assessed by comparison of dose-response
curves. At 10 g/ml, Ag proteins and peptides were almost equally
potent in inducing T cell clone proliferation (Fig. 1 and Table IV).
At lower doses (such as 1 or 0.1 g/ml), the MI obtained with the
appropriate self- or cross-reactive peptide was consistently higher
than that obtained with the corresponding entire Ag.
Data presented in Tables II and III indicate for each clone the most
stimulatory peptides of either hHSP60 or CpHSP60. However, a num-
ber of clones proliferated at lower degree also in response to one or
both of the adjacent peptides, suggesting that their specific epitope
was present in more than one single peptide (Fig. 2).
To know the MHC restriction elements required for Ag recog-
nition, hHSP60-specific T cell clones were stimulated by hHSP60
or CpHSP60 in the presence of irradiated autologous APCs treated
with anti-HLA-DR or anti-HLA-DQ mAbs. Anti-HLA-DR re-
sulted consistently in virtual abrogation of the proliferative re-
sponse by T cell clones to either hHSP60 or CpHSP60, whereas
anti-HLA-DQ was unable to affect self- or cross-reactive HSP60-
induced T cell clone proliferation (data not shown). Because anti-
HLA-DR Abs may hamper T cell responses, even if the specific
response under study is not MHC class II restricted, T cell clones
were stimulated with the relevant hHSP60 peptide in the presence
of either autologous-irradiated PHA-induced T cell blasts or allo-
geneic-irradiated T cell blasts from donors matched for one single
DRB1 allele. As shown in Table V, for most of plaque-derived
clones, the proliferative response to the specific peptide was re-
stricted by one of the DRB1 alleles, whereas for a few clones, both
DRB1 alleles allowed peptide presentation.
Functional profile of autoreactive and cross-reactive hHSP60-
specific T cell clones
All plaque-derived hHSP60-specific clones were assessed for their
cytokine profile on Ag stimulation. In the series of hHSP60-spe-
cific clones not cross-reactive to CpHSP60, 22 (84.6%) secreted
IFN- and TNF- but not IL-4 (Th1 profile), whereas in 4 clones,
stimulation with hHSP60 resulted in the production of IL-4 as well
(Th0 profile).
Likewise, in the series of 18 hHSP60/CpHSP60 cross-reactive
clones, stimulation with either hHSP60 or CpHSP60 disclosed a
Th1 profile in 15 clones (83.3%) and a Th0 profile in the other 3.
The cytolytic potential of hHSP60-specific autoreactive or
cross-reactive T cell clones was assessed by using Ag-pulsed 51Cr-
labeled autologous EBV-B cells as targets. At an E:T ratio of 10:1,
36 of the 37 (97%) Th1 and 5 of 7 (71%) Th0 clones lysed
hHSP60-presenting autologous EBV-B cells (range of specific
51Cr release, 18–63%), whereas autologous EBV-B cells pulsed
with hHSP70 (control) Ag and cocultured with the same clones
Table IV. Cross-reactivity to MbHSP65 and GroEL or to their peptides of CD4 T cell clones reactive to both hHSP60 and
CpHSP60 obtained from the atherosclerotic plaques of anti-C. pneumoniae seropositive patientsa
T Cell Clone Ag or Peptide (position and sequence)
Proliferative Response (MI)a
10 g/ml 1 g/ml 0.1 g/ml
5.05 hHSP60 43 19  2
hHSP60 76–90 DGVTVAKSIDLKDKY 98 56 23
CpHSP60 68 29  2
CpHSP60 51–65 KDGVTVAKEIELEDK 92 61 31
MbHSP65 8  2  2
MbHSP65 51–65 DGVSIAKEIELEDPY 21  2  2
GroEL 13  2  2
GroEL 51–65 KDGVSVAKEIELEDK 28  2  2
5.16 hHSP60 93 34 6
hHSP60 166–180 EEIAQVATISANGDK 138 71 39
CpHSP60 68 29  2
CpHSP60 141–155 HKEIAQVATISANND 101 66 23
MbHSP65 6  2  2
MbHSP65 141–155 QIAATAAISAGDQSI 11  2  2
GroEL 17  2  2
GroEL 141–155 SEEVAQVGTISANGD 31 2  2
8.22 hHSP60 40 19  2
hHSP60 51–65 VAVTMGPKGRTVIIE 69 37 25
CpHSP60 31 14  2
CpHSP60 26–40 AVKVTLGPKGRHVVI 62 29 11
MbHSP65 16  2  2
MbHSP65 26–40 KVTLGPKGRNVVLEK 22  2  2
GroEL 5  2  2
GroEL 26–40 AVKVTLGPKGRNVII 31 2  2
8.26 hHSP60 151 78 22
hHSP60 171–185 VATISANGDKEIGNI 129 84 37
CpHSP60 113 65 30
CpHSP60 146–160 QVATISANNDSEIGN 165 91 36
MbHSP65  2  2  2
MbHSP65 146–160 TAA ISAGDQSIGDLI 9  2  2
GroEL 8  2  2
GroEL 146–160 QVATISANGDKQVGL 22  2  2
a Culture conditions are reported in the legend to Table II. Underlined letters indicate the amino acids shared between hHSP60 and the other HSP60.
Bold letters indicate amino acid changes apparently crucial for peptide recognition by T cell clones 5.05 and 8.22.
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were not lysed. The relative potency of Ag-induced cytotoxic ac-
tivity of HSP60-specific T cell clones against autologous EBV-B
cells pulsed with hHSP60 or CpHSP60 was assessed by compar-
ison of levels of the specific 51Cr release at different E:T ratios
(Fig. 3). Because activated effector T cells can also kill their targets
by inducing apoptosis through Fas-Fas ligand interaction (17, 20),
we evaluated the ability of activated hHSP60-specific clones to
induce 51Cr release by Fas Jurkat cells undergoing apoptosis. On
mitogen activation, 32 of 37 Th1 (86%) and 4 of 7 (57%) Th0
clones were able to induce apoptosis in target cells (range of spe-
cific 51Cr release, 21–59%).
hHSP60-activated plaque-infiltrating T cells help monocyte TF
production
Because plaque rupture and thrombosis are notable complications
of atherosclerosis, we asked whether stimulation with hHSP60 or
CpHSP60 might enable plaque-infiltrating autoreactive or cross-
reactive T cells to express helper function for TF production by
monocytes. All clones were cocultured with autologous monocytes
in the absence or presence of medium alone, hHSP70, hHSP60, or
CpHSP60, and TF protein was measured. In the presence of me-
dium alone or hHSP70, none of the 44 plaque-derived clones ex-
pressed helper function for monocyte TF production, ruling out the
possibility that monocytes expressed hHSP60 suitable for T cell
activation (Fig. 4). In contrast, apart from 2 Th0 clones (one au-
toreactive and one cross-reactive), in 42 (95%) hHSP60-specific
clones, stimulation with hHSP60 resulted in the expression of sub-
stantial help for TF production by monocytes. Likewise, stimula-
tion with CpHSP60 enabled 17 of 18 (94%) cross-reactive T cell
clones to induce monocyte TF production, whereas it failed to
elicit any helper function for TF production in the 25 autoreractive
clones that proliferated in response to hHSP60 but not to CpHSP60
(Fig. 4).
Discussion
A number of Ags are suspected to play a role in atherosclerosis-
associated immune reactions. Among other candidates, the list in-
cludes modified LDL, such as oxidized low-density lipoprotein
(21), viral, and bacterial components, and a family of phylogeneti-
cally highly conserved proteins known as HSPs, which are ex-
pressed in prokaryotic and eukaryotic cells under physiological
conditions and in response to various forms of stress. Under both
normal and stressed conditions, HSPs, as molecular chaperones,
facilitate the folding of nascent proteins, resolubilize protein ag-
gregates, assist in refolding denatured proteins (22), and help in
molecular transport across the intracellular membranes (23). Cells
of the arterial wall are stimulated to produce high levels of HSPs
in response to a number of factors including infections, fever, me-
chanical or oxidant stress, or exposure to cytokines, heavy metals,
alcohol, or inhibitors of energy metabolism (24). Studies in exper-
imental models indicate that 60- to 65-kDa HSP may play a
proatherogenic role. Atherosclerosis-like lesions were induced in
normocholesterolaemic rabbits by immunization with mycobacte-
ria or recombinant mycobacterial HSP65 (25), and T cells isolated
from these lesions were found to respond specifically to HSP65 in
vitro (26, 27).
In this study, we demonstrate that atherosclerotic patients har-
bored in their carotid plaques in vivo-activated CD4 T cells that
reacted specifically to self HSP60. In addition, all four patients
with positive serology and PCR detection of C. pneumoniae DNA
had in their carotid plaques at least two populations of hHSP60-
specific T cells: one reactive only to self hHSP60, and the other
reactive to both the self and the C. pneumoniae analog HSP60.
Blocking experiments with anti-DR and anti-DQ Abs and cocul-
ture of T cell clones with appropriate allogeneic APC showed that
FIGURE 1. Dose-response effect of graded Ag or peptide concentra-
tions on the proliferative response to hHSP60 and CpHSP60 of plaque-
derived T cell clones. T cell blasts from each clone were cocultured with
autologous-irradiated APC in the presence of graded concentrations of
hHSP60 (F), CpHSP60 (E), or of the appropriate hHSP60 peptides (f), or
CpHSP60 peptides (). Results represent mean values of MIs measured in
quadruplicate cultures of 8 representative of 26 clones reactive only to
hHSP60 (upper and middle panels) and in 4 representative of 18 clones
reactive to both hHSP60 and CpHSP60 (lower panels).
FIGURE 2. Proliferative response of hHSP60-specific T-clones to se-
ries of partially overlapping peptides of hHSP60, including the specific
epitopes. T cell blasts from clones derived from the plaques of four patients
sharing the DRB1*07 allele were cocultured with autologous-irradiated
APC in the presence of series of 3 partially overlapping 15-mer peptides,
including the most stimulatory one, and a couple of adjacent peptides.
Results represent mean values of MIs measured in quadruplicate cultures
of eight representative T cell clones.
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DR represents the MHC restriction element in the T cell response
to either hHSP60 or CpHSP60. It is of note that, despite good
viability and IL-2-induced growth, PBMC-derived T cell clones
from all patients consistently failed to proliferate in response to
hHSP60, CpHSP60, or hHSP70. In the absence of obvious expla-
nations due to technical pitfalls, the reason for the inability to
detect hHSP-specific T cells in the peripheral blood remains un-
clear. One possibility is that hHSP60-specific T cells are present in
the peripheral blood in resting state, like most of circulating T
cells, and are not suitable for in vitro activation and expansion
induced by IL-2. Another possibility is that very low numbers, if
any, of in vivo-activated hHSP60-specific T cells are present in the
peripheral blood, whereas they concentrate into the lesions of ar-
terial walls, where they find their specific Ag(s) and participate in
the pathology of atherosclerosis by expressing their effector mech-
anisms. That such activated T cells infiltrating the atherosclerotic
FIGURE 3. Dose-response effect of graded E:T ratios on the cytotoxic
activity of plaque-derived T cell clones specific for hHSP60 against Ag-
pulsed autologous APC. To assess their perforin-mediated cytotoxicity, T
cell clones reactive to hHSP60 (A) or to both hHSP60 and CpHSP60 (B)
were cocultured at different E:T ratios with 51Cr-labeled autologous
EBV-B cells pulsed with hHSP70 (10 g/ml) () or hHSP60 (10 g/ml)
(f) or CpHSP60 (10 g/ml) (Œ), and 51Cr release was measured as index
of Ag-induced specific target cell lysis. Results represent mean values of
51Cr release measured in triplicate cultures of eight representative T cell
clones.
FIGURE 4. Monocyte TF production induced by plaque-derived T cell
clones stimulated with hHSP60 or CpHSP60. T cell blasts from each clone
were cocultured with autologous monocytes in the presence of hHSP70
(control Ag) or the specific Ag (hHSP60 or CpHSP60), and TF production
was assessed by a specific ELISA.
Table V. MHC class II restriction of proliferative response of plaque-derived T cell clones reactive to
selected hHSP60 peptidesa
Code and MHC Class II
Haplotype of Clones
MHC Class II Haplotype of
Irradiated APC
MI in Responsea to hHSP60
Peptide (position)
2.08 DRB103–07 Autologous 108 (31–45)
DRB103 111
DRB107–11 3
2.40 DRB103–07 Autologous 97 (136–150)
DRB103 88
DRB107–11 63
2.53 DRB103–07 Autologous 66 (321–335)
DRB103 7
DRB107–11 52
3.40 DRB101–16 Autologous 71 (91–105)
DRB101–04 4
DRB111–16 65
3.43 DRB101–16 Autologous 36 (206–220)
DRB101–04 29
DRB111–16 2
4.31 DRB104–11 Autologous 54 (446–480)
DRB101–04  2
DRB111–16 49
4.25 DRB104–11 Autologous 112 (491–505)
DRB101–04 89
DRB111–16 3
7.18 DRB103–07 Autologous 68 (46–60)
DRB103 79
DRB107–11  2
Autologous 59 (21–35 of CpHSP60)
DRB103 41
DRB107–11 17
a T cell blasts (105/well) from each clone were cocultured with irradiated autologous or allogeneic activated T cell blasts as
APC (105/well) in the presence of medium alone or the specific hHSP60 or CpHSP60 peptide (10 g/ml), and proliferative
responses (MI) were measured after 3 days. Results are reported as mean values obtained in quadruplicate cultures, SD values
being  16% of means.
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plaques actually participate in the disease pathogenesis is sup-
ported by the observation that the formation of arteriosclerotic le-
sions by immunization of rabbits with HSP65-containing material
could be abolished by immunosuppression and T cell depletion
with an anti-CD3 Ab plus prednisolone (27).
The presence in the plaques of Cp-positive patients of T cells
reactive to CpHSP60 is in agreement with the observations by
other laboratories (28, 29) and with our earlier demonstration in a
similar series of patients of T cells reactive to C. pneumoniae Ags,
such as sonicated elementary bodies, the 10 kDa HSP, the outer
membrane protein 2, and the CpHSP60 (9). In the present study,
however, the presence of plaque-derived T cell clones specific for
C. pneumoniae Ags different from CpHSP60 was not investigated.
T cell recognition of either hHSP60 or CpHSP60 resulted in
both proliferation and expression of functional properties by T cell
clones, i.e., a predominant Th1 profile. In addition, on appropriate
stimulation, the great majority of plaque-derived HSP60-specific
clones induced both perforin-mediated cytolysis and Fas-Fas li-
gand-mediated apoptosis in target cells. Based on these findings, it
is tempting to hypothesize that in the inflammatory setting of the
atherosclerotic plaque in which HSP60-specific autoreactive or
cross-reactive Th1 cells are activated, endothelial cells may ac-
quire APC function for HSP60 and, together with professional
APCs (30), can become targets of the cytotoxic and proapoptotic
activity of HSP60-specific Th1 cells. The outcome of this process
would be the expansion of the plaque and the formation of the
necrotic cores characteristic of complicated and unstable athero-
sclerotic lesions. A linkage has been suggested between the degree
of macrophage apoptosis and plaque rupture, to which apoptotic
death of smooth muscle cells may also contribute (31–33). More-
over, it is reasonable to suspect that HSP60-activated Th1 cells and
their cytokines can play a role in driving the up-regulation of TF
production by monocytes within atherosclerotic plaques, thus con-
tributing to the thrombogenicity of lesions (34). Indeed, the Th1
polarization of T cell responses and the poor production of Th2
cytokines occurring within the plaque may represent local risk fac-
tors of thrombosis (19), which associate with platelet adhesion to
dysfunctional endothelium.
Our findings support the hypothesis that a crucial component of
atherosclerosis is represented by Th1 cell-mediated immune re-
sponses to self and/or foreign Ags. More than 95% sequence ho-
mology exists between HSP60s from various bacteria, and even
between bacterial and hHSP60 a 50–55% sequence homology ex-
ists, and in highly conserved regions it reaches 70% (35). The
analysis of the submolecular specificity of T cell clones reactive
only to hHSP60 and of clones reactive to both hHSP60 and
CpHSP60 showed that the former recognized their epitope in por-
tions of relatively poor or no homology between the two proteins,
whereas the latter found their specific epitope in regions of high-
sequence homology. Therefore, a number of hHSP60 T cell
epitopes are “private,” such as the 1–15 and 6–20 N-terminal or
the 506–520 C-terminal sequences recognized by different clones
of different Cp-negative patients and by a few clones of Cp-posi-
tive patients, whereas other hHSP60 epitopes are similar to, and
cross-reactive with, T cell epitopes of CpHSP60. T cell clones
specific for private or cross-reactive epitopes of hHSP60 do, how-
ever, express similar predominant Th1 profile and may contribute
equally to inflammation in the setting of atherosclerosis.
HSP60 are released in soluble form from the surface of stressed
or damaged cells and can be found in the supernatant of cell cul-
tures in vitro or in the serum in vivo (36, 37). Whether soluble
hHSP60 released in the inflammatory setting of the plaque may
undergo biochemical changes, becoming the target of bona fide
autoimmunity (3), remains to be investigated. Likewise, it remains
to be established whether autoimmunity to hHSP60 results from a
breakdown of tolerance associated with chronic inflammation and
aging, and what is the role of the molecular mimicry between
hHSP60 and the HSP60 of pathogens, such as C. pneumoniae,
detected in the atherosclerotic lesions. The mycobacterial homo-
logue MbHSP65 and the E. coli homologue GroEL (38) might be
other candidates for cross-reactive recognition by hHSP60-reac-
tive T cell clones in atherosclerotic plaques. In this study, however,
none of the 26 T cell clones reactive to hHSP60, but not to
CpHSP60, also reacted to MbHSP65 or to GroEL. Only 11 and 9
of the 18 T cell clones reactive to both hHSP60 and CpHSP60
showed poor or negligible response to MbHSP65 or GroEL, re-
spectively, on the basis of dose-response curves. Neither
MbHSP65 nor GroEL peptides that partially overlapped specific
hHSP60/CpHSP60 epitopes were able to induce T cell clone pro-
liferation at intermediate or low peptide concentrations, arguing
against the hypothesis that MbHSP65 or GroEL might represent
major targets of plaque-infiltrating T cells in our patients.
Data obtained in this study support the hypothesis that two ma-
jor mechanisms, partially overlapping and not mutually exclusive,
may be responsible for the T cell-mediated immunopathology of
atherosclerosis. The first one would imply that arterial endothelial
cells, undergoing the effects of classical stress factors associated
with atherosclerosis and conditioned by cytokines produced by
plaque-infiltrating Th1 cells, express self 60-kDa HSP. Such an
autoantigen would be presented by professional APC and endo-
thelial cells, becoming a target of autoreactive T cells specific for
private epitopes of hHSP60. T cell-mediated cytotoxic and apo-
ptotic killing of stressed endothelial cells expressing self HSP60
may activate a vicious circle of self maintenance of such Th1-
mediated autoimmune mechanism of endothelial damage. The sec-
ond mechanism, active in patients who failed to clear C. pneu-
moniae, would be mediated by plaque-infiltrating Th1 cells
specific for C. pneumoniae Ags, among which CpHSP60-specific
T cells that cross-recognize shared epitopes of the hHSP60 via a
mechanism of molecular mimicry. The availability of self HSP60
expressed by the vascular endothelium would contribute to a sec-
ond branch of the vicious circle of self maintenance of the immune
response that would be mediated by CpHSP60-specific Th1 cells
that cross-react to self HSP60. These possibilities are consistent
with the results obtained in several experimental animal models. In
these models, a central role for T cells specific for HSP60s has
indeed been established. Immunization with HSP65 of LDL re-
ceptor-deficient (LDL-R/) mice induced specific T cell reactiv-
ity against HSP65 as well as mammalian HSP60, and transfer into
nonimmunized mice of lymphocytes or purified IgG of immunized
animals enhanced the size of vascular lesions (39). In contrast,
nasal or oral immunization with HSP65 of hypercholesterolemic
ApoE/ and LDL-R/ mice resulted in reduced T cell reactivity
to HSP and attenuated atherosclerosis (40, 41). In contrast, arthri-
togenic and arthritis-preventing HSP60 epitopes have been iden-
tified in the model of adjuvant arthritis in rats (42, 43) and human
rheumatoid arthritis (44). The identification in present study of a
number of atherosclerosis-associated T cell epitopes of HSP60
may be of importance for designing strategies on preventive or
therapeutic approaches aimed to inhibit the immune and autoim-
mune pathogenic mechanisms of atherosclerosis.
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